Global Biotech Market Outlook: Capitalizing on Next-Gen Therapeutics
The global biotech market is entering 2026 with a different investment profile from the one that defined the pandemic-era funding boom. Capital is returning, dealmaking has strengthened and public-market access has improved, but the recovery is not broad-based. Investors and pharmaceutical companies are increasingly distinguishing between scientific potential and assets that have demonstrated enough evidence…